MindMed Increases Cash on Hand to CAD $205.2m , Closes Financing of CAD $19.5m

- March 9th, 2021

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Mind Medicine Inc. is pleased to announce that it has closed its previously announced bought deal private placement offering . In connection with the Offering, the Company issued 6.0 million units of the Company at a price per Unit of CAD $3.25 for gross proceeds of CAD $19.5 million . The Offering was conducted by …

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF, DE: MMQ) (“MindMed” or the “Company”) is pleased to announce that it has closed its previously announced bought deal private placement offering (the “Offering”). In connection with the Offering, the Company issued 6.0 million units of the Company (the “Units”) at a price per Unit of CAD $3.25 (the “Issue Price”) for gross proceeds of CAD $19.5 million . The Offering was conducted by Canaccord Genuity Corp. (the “Underwriter”) pursuant to an underwriting agreement dated March 9, 2021 between the Company and the Underwriter.

MindMed is a leading psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness. Following the closing of the Offering, the Corporation’s cash on hand has increased to CAD $205.2 million (USD $162.0 million ). Since the founding of Mind Medicine, Inc. in May 2019 , MindMed has now raised a total of approximately CAD $256.7 million (USD $202.7 million ) in investment capital before fundraising and deal expenses, making it one of the leaders in the psychedelic medicine industry in its ability to finance its innovative R&D, a new digital therapeutics division and a growing clinical trial pipeline.

MindMed Co-Founder & CEO, J.R. Rahn said, “As we march forward with our uplisting plans for Nasdaq and the overall advancement of the MindMed portfolio, we saw it as a timely opportunity to bring in a strategic investor to support MindMed’s future growth initiatives. In the years ahead, I believe MindMed will be viewed as much as a digital medicine platform as it is a pharmaceutical drug development company.”

The net proceeds of the Offering will be used for further investment in Project Lucy (experiential LSD), the Microdose LSD Program and Project Albert, which is  now integrating MindMed’s most recent technology acquisition, HealthMode, to build a comprehensive mental health platform to deploy psychedelics medicines, and for general working capital purposes.

Further Details of Offering

In connection with the Offering, the Company issued 6.0 million Units at the Issue Price for gross proceeds of CAD $19.5 million .

Each Unit comprises one subordinate voting share of the Company (each, a “Subordinate Voting Share”) and one-half of one Subordinate Voting Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Subordinate Voting Share at an exercise price of CAD $4.40 until March 9, 2024 . If, at any time following the date that is four months and one day following the closing of the Offering, the daily volume weighted average trading price of the Subordinate Voting Shares on the Neo Exchange Inc. is greater than CAD $6.90 per Subordinate Voting Share for the preceding five consecutive trading days, the Company may, upon providing written notice to the holders of Warrants, accelerate the expiry date of the Warrants to the date that is at least 30 days following the date of such written notice.

The Subordinate Voting Shares and Warrants underlying the Units issued pursuant to the Offering are subject to a hold period of four months and one day following the closing of the Offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933 , as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933 , as amended, and applicable state securities laws.

About MindMed

MindMed is a leading psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the Company’s groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies.

MindMed trades on the Neo Exchange Inc. under the symbol MMED . MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ . For more information: www.mindmed.co .

Forward-Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the intended use of proceeds of the Offering, the Company’s cash reserves and the effects thereof, and the Company’s intended future business plans and operations, including the development of psychedelic inspired medicines and experiential therapies. There are numerous risks and uncertainties that could cause actual results and MindMed’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Media Contact: mindmed@150bond.com

SOURCE Mind Medicine (MindMed) Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2021/09/c3931.html

News Provided by Canada Newswire via QuoteMedia

 

Start Here:
Investing in Psychedelics

   
Curious about this new market?
Find out what new psychedelics investors need to know.
 

Leave a Reply